| 20.8662 -0.734 (-3.4%) | 09-23 10:42 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.23 | 1-year : | 30.01 |
| Resists | First : | 23.32 | Second : | 25.7 |
| Pivot price | 21.24 |
|||
| Supports | First : | 19.46 | Second : | 16.19 |
| MAs | MA(5) : | 20.6  |
MA(20) : | 21.95 |
| MA(100) : | 22.51 |
MA(250) : | 20.07 |
|
| MACD | MACD : | -1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 35.7 |
D(3) : | 23.3 |
| RSI | RSI(14): 41.5 |
|||
| 52-week | High : | 27.29 | Low : | 13.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DNLI ] has closed above bottom band by 45.7%. Bollinger Bands are 3.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.82 - 21.91 | 21.91 - 21.99 |
| Low: | 20.27 - 20.36 | 20.36 - 20.45 |
| Close: | 21.44 - 21.6 | 21.6 - 21.74 |
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Fri, 18 Sep 2026
Denali Therapeutics Stock Price Forecast. Should You Buy DNLI? - StockInvest.us
Sat, 05 Sep 2026
Denali Therapeutics director sells $261,928 in stock - Investing.com
Fri, 04 Sep 2026
Denali Therapeutics (NASDAQ: DNLI) holder to sell shares to cover tax on stock units - Stock Titan
Wed, 19 Aug 2026
Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI) - Seeking Alpha
Thu, 13 Aug 2026
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI) - Seeking Alpha
Wed, 29 Jul 2026
Denali Therapeutics nearly doubles its winnings from first drug approval - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 160 (M) |
| Held by Insiders | 1.5508e+008 (%) |
| Held by Institutions | 9 (%) |
| Shares Short | 16,040 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.2606e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 601.2 % |
| Return on Equity (ttm) | -29.2 % |
| Qtrly Rev. Growth | 3.6e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -54.94 |
| EBITDA (p.s.) | -3.9721e+008 |
| Qtrly Earnings Growth | -2.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -434 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.39 |
| Price to Cash Flow | 4.03 |
| Dividend | 0 |
| Forward Dividend | 1.796e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|